Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Advanced or Metastatic Cervical Cancer
NCT04865887Phase 2Recruiting
- Sponsor
- Georgetown University
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in Cervical Cancer (CC), sponsored by Georgetown University. Started Oct 2022; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04865887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865887.